Amid concerns over the third wave of COVID-19 to impact the kids, the government has been mulling ways to prepare for the same.
Niti Aayog Member Dr VK Paul on Tuesday said that the COVIAXIN trials in the age group of 2 to 18 years will begin in the next 10-12 days.
“COVAXIN has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days,” said Dr. VK Paul, Member-Health, Niti Aayog.
Source link
